Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01001377 · OUTCOME

Time to Response

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer · Source last updated 2022-09-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Inter-Quartile Range
Time frame
From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.

What was measured

Time to response (TTR), calculated for those participants with an objective response, is defined as the time from the randomization date to the date of first objective response.

Analysis population: Participants with an objective response

Groups in this outcome

Cetuximab

Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.

Panitumumab

Panitumumab 6 mg/kg IV every 14 days.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cetuximab96
Panitumumab107

Reported measurements

Source class 1
Values in months · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
Cetuximab2.6Not reported1.23.1Not reported
Panitumumab1.5Not reported1.23.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.2
        upper Limit
        3.1
        value
        2.6
      2. group Id
        OG001
        lower Limit
        1.2
        upper Limit
        3.0
        value
        1.5
denoms
  1. counts
    1. group Id
      OG000
      value
      96
    2. group Id
      OG001
      value
      107
    units
    Participants
description
Time to response (TTR), calculated for those participants with an objective response, is defined as the time from the randomization date to the date of first objective response.
dispersion Type
Inter-Quartile Range
groups
  1. description
    Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
    id
    OG000
    title
    Cetuximab
  2. description
    Panitumumab 6 mg/kg IV every 14 days.
    id
    OG001
    title
    Panitumumab
param Type
MEDIAN
population Description
Participants with an objective response
reporting Status
POSTED
time Frame
From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
title
Time to Response
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice